ORTHO-NOVUM 2-21 Drug Patent Profile
When do Ortho-novum 2-21 patents expire, and what generic alternatives are available?
Ortho-novum 2-21 is a drug marketed by Ortho Mcneil Pharm and is included in one NDA.
The generic ingredient in ORTHO-NOVUM 2-21 is mestranol; norethindrone. There is one drug master file entry for this compound. Additional details are available on the mestranol; norethindrone profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ORTHO-NOVUM 2-21?
- What are the global sales for ORTHO-NOVUM 2-21?
- What is Average Wholesale Price for ORTHO-NOVUM 2-21?
Summary for ORTHO-NOVUM 2-21
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Patent Applications: | 89 |
| DailyMed Link: | ORTHO-NOVUM 2-21 at DailyMed |
US Patents and Regulatory Information for ORTHO-NOVUM 2-21
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ortho Mcneil Pharm | ORTHO-NOVUM 2-21 | mestranol; norethindrone | TABLET;ORAL-21 | 012728-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Ortho-Novum 2/21 Market Dynamics, Patent Status, and Financial Trajectory
Ortho-Novum 2/21 is an older combined oral contraceptive containing norethindrone 1 mg and ethinyl estradiol 35 mcg. Its commercial value is now tied to the broader generic oral-contraceptive market rather than to a protected branded franchise. Core composition patents and regulatory exclusivities expired decades ago, no current standalone Ortho-Novum 2/21 revenue is disclosed by the brand owner, and generic substitution has eliminated meaningful pricing power.[1][2]
What is Ortho-Novum 2/21?
Ortho-Novum 2/21 is a monophasic combined oral contraceptive. Each active tablet contains:
| Attribute | Ortho-Novum 2/21 |
|---|---|
| Progestin | Norethindrone, 1 mg |
| Estrogen | Ethinyl estradiol, 35 mcg |
| Dosage form | Oral tablet |
| Regimen | 21 active tablets followed by a hormone-free interval |
| Therapeutic category | Combined hormonal contraception |
| Original commercial sponsor | Ortho-McNeil, later associated with Johnson & Johnson pharmaceutical operations |
| Current commercial position | Legacy brand with generic competition |
| Biosimilar relevance | None; this is a small-molecule drug |
The "2/21" designation distinguishes the product from Ortho-Novum 1/35 and Ortho-Novum 7/7/7. The products use different hormone strengths or dosing patterns and should not be treated as interchangeable brand products without reference to their approved generic equivalents.
Is Ortho-Novum 2/21 still marketed?
The original Ortho-Novum franchise has largely exited the U.S. branded market. Current U.S. contraceptive demand is supplied primarily by generic norethindrone and ethinyl estradiol products, newer oral contraceptives, long-acting reversible contraceptives, and over-the-counter or prescription alternatives.
The market position is best described as legacy-brand discontinuation or commercial withdrawal rather than active branded growth. A product may remain listed in historical FDA records after commercial distribution ends. FDA databases distinguish between approval status, marketing status, and discontinuation reporting, so a historical NDA listing does not establish current availability.[1]
What products compete with Ortho-Novum 2/21?
The closest substitutes are generic norethindrone/ethinyl estradiol tablets with the same dosage strength and regimen. Broader competitors include:
- Norethindrone/ethinyl estradiol 1 mg/35 mcg generics
- Norethindrone/ethinyl estradiol/ferrous fumarate products
- Levonorgestrel/ethinyl estradiol products
- Norgestimate/ethinyl estradiol products
- Drospirenone/ethinyl estradiol products
- Progestin-only pills
- Etonogestrel implants
- Levonorgestrel intrauterine systems
- Depot medroxyprogesterone acetate injections
- Transdermal and vaginal contraceptive systems
Substitution pressure is strongest from low-cost generic combined oral contraceptives and long-acting methods that reduce daily adherence requirements.
When did Ortho-Novum 2/21 lose exclusivity?
Ortho-Novum 2/21 lost meaningful market exclusivity many years ago. The product’s active ingredients are established small molecules, and the relevant composition and formulation patents have expired. No current patent-based exclusivity supports a premium branded price.
| Exclusivity category | Current position |
|---|---|
| New chemical entity exclusivity | Expired |
| Original composition patents | Expired |
| Formulation patents | No commercially relevant unexpired estate identified |
| Pediatric exclusivity | Not commercially relevant |
| Orphan-drug exclusivity | Not applicable |
| Biologic exclusivity | Not applicable |
| Data exclusivity | Expired |
| Generic competition | Established |
The historical age of the product means that patent expiry, rather than a recent Paragraph IV event, explains the competitive outcome. The Hatch-Waxman patent framework remains relevant to generic entry, but it no longer creates a practical barrier for this product.[3]
What patents protect Ortho-Novum 2/21?
No active U.S. patent estate appears to protect the commercial use of the legacy Ortho-Novum 2/21 product. Early oral-contraceptive patents covering estrogen-progestin combinations and tablet formulations expired well before the current period.
The relevant intellectual-property position can be summarized as follows:
| IP issue | Assessment |
|---|---|
| Active ingredient patents | Expired |
| Combination patent protection | Expired |
| 21-day regimen protection | Expired or commercially irrelevant |
| Tablet formulation protection | Expired |
| Method-of-use patents | No material current protection identified |
| Manufacturing know-how | Possible at the supplier level, but not a barrier to generic approval |
| Trademark protection | May persist independently of product-market exclusivity |
A trademark can remain registered after patents expire, but trademark rights protect branding rather than the norethindrone/ethinyl estradiol formulation. They do not prevent FDA-approved generic substitution.
What is the FDA regulatory status of Ortho-Novum 2/21?
Ortho-Novum 2/21 was approved as a prescription combined oral contraceptive. Its regulatory profile is materially different from modern contraceptive products because the active ingredients have extensive clinical and regulatory histories.
The FDA approval pathway for a generic equivalent is generally an abbreviated new drug application. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference-listed drug rather than repeat the full clinical development program required for an innovative product.[1][4]
Regulatory characteristics include:
- Prescription status in the United States
- Small-molecule drug classification
- No biologic license application
- No biosimilar pathway
- No orphan designation
- No current exclusivity advantage based on the legacy brand
- Generic substitution governed by state pharmacy law and payer formularies
What is the Orange Book status of Ortho-Novum 2/21?
The Orange Book is relevant for identifying approved products, reference-listed-drug relationships, therapeutic-equivalence codes, and patent or exclusivity information. For a legacy contraceptive, the commercial question is whether an active reference-listed drug and therapeutically equivalent generic products remain available, not whether the historical brand once held an Orange Book patent listing.[1]
The practical Orange Book implications are:
- Historical brand approval does not guarantee current distribution.
- Generic approvals can remain commercially viable after the brand stops marketing.
- Patent listings, if any, have no meaningful blocking effect after expiration.
- Therapeutic-equivalence listings support pharmacy substitution where state law permits it.
How many patents cover Ortho-Novum 2/21?
No active U.S. patents with material blocking value are apparent for Ortho-Novum 2/21. Historical patent counts are less informative than expiry dates because the product has been exposed to generic competition for decades.
A reasonable commercial classification is:
| Patent category | Blocking value today |
|---|---|
| Active ingredient patents | 0 |
| Original combination patents | 0 |
| Active formulation patents | 0 identified |
| Active method-of-use patents | 0 identified |
| Manufacturing patents | Potentially relevant to individual suppliers, not the product market |
| Trademark rights | Brand protection only |
This is a low-strength patent estate. Any future commercial value would come from manufacturing economics, distribution, contracting, or brand recognition rather than exclusivity.
Which companies compete in the norethindrone and ethinyl estradiol market?
Competition is fragmented across generic manufacturers, contract manufacturers, wholesalers, and pharmacy suppliers. Companies that have marketed or supplied oral contraceptive products in the broader U.S. market include Teva, Lupin, Glenmark, Amneal, Aurobindo, Prasco, Xiromed, and other FDA-approved generic suppliers. Product availability changes as manufacturers discontinue NDCs, change suppliers, or adjust portfolio priorities.
The relevant competitive variables are:
- Lowest sustainable acquisition cost
- Reliable active pharmaceutical ingredient supply
- FDA manufacturing compliance
- Wholesaler access
- Medicaid and commercial-plan formulary placement
- Inventory continuity
- Ability to supply multiple package configurations
- Pricing discipline in a commoditized market
The market does not require a large sales force. Generic suppliers compete primarily through manufacturing scale, contracting, and channel access.
What is the financial trajectory for Ortho-Novum 2/21?
No standalone revenue, operating-profit, or unit-volume series for Ortho-Novum 2/21 is disclosed in Johnson & Johnson public filings. The product’s historical sales were incorporated into broader pharmaceutical or women’s-health portfolios and were not reported as a separately material segment.[5]
The financial trajectory is therefore best modeled in four phases:
| Period | Financial condition |
|---|---|
| Original launch and branded growth | Revenue supported by physician prescribing and brand recognition |
| Generic-entry period | Price and share erosion after loss of exclusivity |
| Portfolio maturity | Lower volumes, reduced promotional investment, and broader substitution |
| Current legacy phase | Little or no attributable branded revenue; generic market economics dominate |
The principal financial conclusion is that Ortho-Novum 2/21 has no identifiable current blockbuster exposure. Its contribution to the former brand owner’s consolidated revenue is immaterial relative to major pharmaceutical products, and the product does not represent a meaningful earnings driver.
What revenue exposure remains?
Revenue exposure may persist through:
- Residual sales under legacy branding in limited markets
- Licensing or supply arrangements
- Contract manufacturing
- Generic products containing the same active ingredients
- Portfolio-level revenue not separately attributed to the product
These channels should not be treated as Ortho-Novum 2/21 brand revenue. Public company disclosures generally aggregate mature products into therapeutic-area or geographic categories.
Are there Paragraph IV challenges to Ortho-Novum 2/21?
Paragraph IV litigation is not a current commercial issue for the legacy product. A Paragraph IV certification challenges the validity, enforceability, or infringement of listed patents when a generic applicant seeks approval before patent expiry. Because the relevant Ortho-Novum 2/21 exclusivity period ended long ago, generic entry does not depend on a contemporary patent challenge.[3]
Any historical ANDA litigation would have limited present value unless it affected an active patent or a continuing settlement restriction. No such current restriction is commercially material for the legacy product.
What patent litigation affects Ortho-Novum 2/21?
No material current U.S. patent litigation is associated with Ortho-Novum 2/21. Litigation risk is low because:
- The active ingredients are long-established.
- The legacy formulation is conventional.
- Original patent protection has expired.
- Generic products are already established.
- There is no apparent active patent covering a differentiated delivery system.
Potential disputes would more likely involve product liability, manufacturing quality, labeling, supply agreements, or trademark use than patent infringement.
Are there settlement agreements restricting generic launch?
No current generic-launch settlement appears to constrain the market for Ortho-Novum 2/21. Settlement agreements are generally relevant when a brand company has an unexpired patent and agrees to a date-certain generic launch, authorized generic supply, or other market-access terms. That structure has little relevance to a legacy contraceptive whose core exclusivity has expired.
What formulations are protected by Ortho-Novum 2/21 patents?
No commercially relevant protected formulation has been identified. Ortho-Novum 2/21 uses a conventional immediate-release oral tablet rather than an extended-release system, implant, transdermal delivery platform, or other complex dosage form.
This limits manufacturing and regulatory barriers. A competing manufacturer does not need to replicate a proprietary device or complex release mechanism. It must produce a pharmaceutically equivalent product meeting applicable quality, stability, dissolution, and bioequivalence requirements.
How strong is the patent estate for Ortho-Novum 2/21?
The patent estate is weak from an investment or litigation perspective.
| Strength factor | Rating |
|---|---|
| Remaining patent term | None of material value |
| Claim breadth | Historically broad, currently expired |
| Formulation differentiation | Low |
| Manufacturing complexity | Low to moderate |
| Generic substitution risk | Very high |
| Litigation leverage | Very low |
| Pricing power | Minimal |
| Reinvestment case | Weak unless tied to a new product or delivery platform |
Manufacturing can still create operational barriers. Hormonal APIs require controlled handling, validated processes, quality systems, and compliant facilities. Those requirements affect supplier reliability but do not recreate product exclusivity.
What generic launch scenarios exist?
Three scenarios describe the current market:
Continued generic supply
This is the base case. Multiple suppliers maintain low-cost norethindrone/ethinyl estradiol products, with intermittent NDC-level changes caused by capacity, API availability, or commercial reprioritization.
Supplier consolidation
A manufacturer exits the product, leaving fewer suppliers and temporary price increases. Such an event would reflect supply concentration rather than patent protection.
Brand revival or relaunch
A relaunch would require marketing investment, reliable supply, and payer or pharmacy differentiation. A legacy brand would face substantial difficulty charging a premium against therapeutically equivalent generics unless supported by a specialized distribution strategy.
How does Ortho-Novum 2/21 compare with newer contraceptives?
| Factor | Ortho-Novum 2/21 | Newer branded contraceptives |
|---|---|---|
| Active ingredients | Norethindrone/ethinyl estradiol | Varies |
| Patent position | Expired | May include active formulation or use patents |
| Price power | Low | Potentially higher |
| Differentiation | Limited | May include tolerability, regimen, or delivery claims |
| Generic risk | Established | Depends on patent and regulatory status |
| Adherence profile | Daily oral dosing | Oral, transdermal, vaginal, injectable, or implant |
| Commercial growth | Mature or declining | Product-specific |
| Litigation exposure | Low | Potentially significant |
The key competitive disadvantage is the absence of differentiation. Patients and prescribers can select from many combined hormonal contraceptives, while payers typically favor low-cost generic options.
What geographic markets still matter?
The economic profile differs by jurisdiction:
- United States: mature generic market with strong substitution and payer pressure.
- Europe: national reimbursement systems and generic tendering reduce branded pricing.
- Emerging markets: lower prices but potential demand growth, local manufacturing, and regulatory variation.
- Latin America: brand recognition may persist longer, but local generic and branded-generic competition remains strong.
- Asia-Pacific: market access depends on national registration, local supply, and prescription or pharmacy rules.
Trademark recognition can persist in individual countries even after patent expiry. That distinction may support limited branded sales but does not produce broad exclusivity.
Key Takeaways
- Ortho-Novum 2/21 is a legacy combined oral contraceptive containing norethindrone 1 mg and ethinyl estradiol 35 mcg.
- Its core patents and regulatory exclusivities expired decades ago.
- No material active U.S. patent estate or current patent litigation supports the product.
- Generic competition has removed meaningful pricing power.
- No standalone current revenue is disclosed for the product.
- The principal risks are generic substitution, supplier consolidation, and declining brand relevance.
- Manufacturing and quality requirements remain operational barriers, but they do not create market exclusivity.
- The product has low strategic value unless considered as part of a broader generic contraceptive portfolio.
FAQs About Ortho-Novum 2/21
Is Ortho-Novum 2/21 the same as Ortho-Novum 1/35?
No. Both are combined oral contraceptives, but Ortho-Novum 2/21 and Ortho-Novum 1/35 use different product formulations or strength designations. Substitution should be based on the approved generic equivalent and prescribing information.
Can a company launch a generic version of Ortho-Novum 2/21?
Yes. The product is an established small-molecule formulation with no apparent current patent barrier of material commercial significance. Approval would generally proceed through the ANDA pathway if an appropriate reference product is available.
Does Ortho-Novum 2/21 have biosimilar competition?
No. Biosimilar rules apply to biological products. Ortho-Novum 2/21 is a conventional small-molecule drug, so competition occurs through generic-drug approvals.
Could the Ortho-Novum trademark still be valuable?
Possibly, but trademark value is separate from patent value. Brand recognition may support limited sales in selected markets, but it does not prevent generic manufacturers from selling therapeutically equivalent products.
Is Ortho-Novum 2/21 a viable licensing asset?
As a standalone branded asset, it has limited licensing value. A transaction would require a low-cost supply position, established distribution, geographic brand rights, or inclusion in a broader contraceptive portfolio.
References
- U.S. Food and Drug Administration. (2024). Drugs@FDA and Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). https://www.fda.gov/drugs
- U.S. National Library of Medicine. (2024). DailyMed: Norethindrone and ethinyl estradiol prescribing information. https://dailymed.nlm.nih.gov
- U.S. Food and Drug Administration. (2018). Abbreviated new drug application approvals and patent certifications under the Hatch-Waxman Amendments. https://www.fda.gov/drugs
- U.S. Food and Drug Administration. (2024). Generic drug facts and ANDA requirements. https://www.fda.gov/drugs/generic-drugs
- Johnson & Johnson. (Various years). Annual reports and Form 10-K filings. https://www.investor.jnj.com/financials.cfm
More… ↓
